Market Cap 10.67B
Revenue (ttm) 393.50M
Net Income (ttm) -409.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -103.97%
Debt to Equity Ratio -4.46
Volume 456,500
Avg Vol 432,428
Day's Range N/A - N/A
Shares Out 61.15M
Stochastic %K 97%
Beta 0.41
Analysts Strong Sell
Price Target $227.62

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candid...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 22 22 44
Address:
Tuborg Boulevard 12, Hellerup, Denmark
Doozio
Doozio Aug. 4 at 6:57 PM
Da huckleberries shall $ASND thru da $$$$ n smoke them 🐑 fools! 🐒🍌🧠⏰♾️
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 1 at 6:25 PM
If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS
0 · Reply
RiskEprofit
RiskEprofit Jul. 28 at 2:00 PM
$ASND 😂🤣😂🤣
0 · Reply
Pika_Capital
Pika_Capital Jul. 28 at 1:39 PM
$ASND another approval in the bag. Waiting for my $200+. It's coming
2 · Reply
Whiskey1679
Whiskey1679 Jul. 27 at 5:13 PM
Whiskeys Penny Stock Picks out tomorrow by 6:20 am PDT!! Trending: $COSM $APLS $ASND $ABOS $ANVS
1 · Reply
Laurentium
Laurentium Jul. 25 at 3:14 PM
$ASND Eyes on the prize
0 · Reply
RiskEprofit
RiskEprofit Jul. 23 at 11:42 PM
$ASND The quiet period before the actual storm comes. 🎫
0 · Reply
StockWriter69
StockWriter69 Jul. 23 at 10:33 AM
$ASND does anyone know the date when will the publish if they got approval or not?
1 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 6:54 PM
$ASND Information regarding Bank of America analyst report on ASND issued today: https://x.com/CorleoneDon77/status/1944827475806040472
0 · Reply
belsimtaq7
belsimtaq7 Jul. 8 at 8:29 AM
$ASND very tight for the past 5 weeks. Once it passes ATH, over 185 it's clear sky, any day now
0 · Reply
Latest News on ASND
FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 2 months ago

FDA Accepts TransCon® CNP NDA for Priority Review


Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:35 PM EDT - 3 months ago

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript


Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 3 months ago

Ascendis Pharma Reports First Quarter 2025 Financial Results


Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 11:03 PM EST - 6 months ago

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript


Ascendis Pharma: Danish Blockbuster Hunter

Jan 29, 2025, 12:31 AM EST - 6 months ago

Ascendis Pharma: Danish Blockbuster Hunter


Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:53 PM EST - 9 months ago

Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript


Ascendis Pharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 9 months ago

Ascendis Pharma Reports Third Quarter 2024 Financial Results


Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Sep 19, 2024, 8:16 PM EDT - 11 months ago

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs


Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Sep 18, 2024, 4:04 PM EDT - 11 months ago

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs


Ascendis Pharma Takes A Big Price Cut On Skytrofa

Sep 5, 2024, 1:30 AM EDT - 11 months ago

Ascendis Pharma Takes A Big Price Cut On Skytrofa


Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript

Sep 3, 2024, 9:41 PM EDT - 11 months ago

Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript


Ascendis Pharma Reports Second Quarter 2024 Financial Results

Sep 3, 2024, 5:04 PM EDT - 11 months ago

Ascendis Pharma Reports Second Quarter 2024 Financial Results


FDA approves Ascendis Pharma's hormone disorder therapy

Aug 12, 2024, 7:23 AM EDT - 1 year ago

FDA approves Ascendis Pharma's hormone disorder therapy


Doozio
Doozio Aug. 4 at 6:57 PM
Da huckleberries shall $ASND thru da $$$$ n smoke them 🐑 fools! 🐒🍌🧠⏰♾️
0 · Reply
TrendEdgeLogan
TrendEdgeLogan Aug. 1 at 6:25 PM
If you're not looking at biotech stocks today idk what you are looking at. $XBI $IBB $ONC $CNTA $ASND KNSA, MIRM, ALNY, SPRY, XERS
0 · Reply
RiskEprofit
RiskEprofit Jul. 28 at 2:00 PM
$ASND 😂🤣😂🤣
0 · Reply
Pika_Capital
Pika_Capital Jul. 28 at 1:39 PM
$ASND another approval in the bag. Waiting for my $200+. It's coming
2 · Reply
Whiskey1679
Whiskey1679 Jul. 27 at 5:13 PM
Whiskeys Penny Stock Picks out tomorrow by 6:20 am PDT!! Trending: $COSM $APLS $ASND $ABOS $ANVS
1 · Reply
Laurentium
Laurentium Jul. 25 at 3:14 PM
$ASND Eyes on the prize
0 · Reply
RiskEprofit
RiskEprofit Jul. 23 at 11:42 PM
$ASND The quiet period before the actual storm comes. 🎫
0 · Reply
StockWriter69
StockWriter69 Jul. 23 at 10:33 AM
$ASND does anyone know the date when will the publish if they got approval or not?
1 · Reply
DonCorleone77
DonCorleone77 Jul. 14 at 6:54 PM
$ASND Information regarding Bank of America analyst report on ASND issued today: https://x.com/CorleoneDon77/status/1944827475806040472
0 · Reply
belsimtaq7
belsimtaq7 Jul. 8 at 8:29 AM
$ASND very tight for the past 5 weeks. Once it passes ATH, over 185 it's clear sky, any day now
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 7 at 1:46 AM
$ADMA trades at 0.43X cumulative 10-year analyst consensus revenue estimates. It's our experience most commercial-stage biopharma M&A transactions are priced at 0.32 to 0.41X 10-year projected revenues (most does not mean all). We genuinely struggle to understand the ADMA value proposition when, in addition to trading at a high revenue multiple, ADMA generates gross profit/margins well below others in this peer group. This is not to bash ADMA. We'd genuinely like to understand the disconnect. $APLS & $AXSM continue to trade at revenue multiples lower than their peers. $TGTX & $ASND trade at higher multiples than peers. This is not investment advice but we suspect this is due to the confidence in their therapies (so no need to discount as aggressively in NPV calcs). We track these data points manually so of course we may have made a mistake.
4 · Reply
Doozio
Doozio Jul. 3 at 7:59 PM
$XBI $IWM chop chop huckleberries n da 🧠 shall spread/ rotate thru all da huckleberries and $ASND thru da $$$$ patterns TTWO $BYRN and SEZL da 🐑 during 🐒🍌🧠⏰♾️
1 · Reply
JarvisFlow
JarvisFlow Jul. 3 at 5:24 PM
Morgan Stanley has adjusted their stance on Ascendis Pharma ( $ASND ), setting the rating to Overweight with a target price of 250.
0 · Reply
SparkyReturns
SparkyReturns Jul. 2 at 2:46 PM
$MRNA Here's an Investing idea. Anyone remember when I gave this tip about ICU a few times in the last week...? Yeah. Just getting started. Expect a 10x +. $BMRN $ASND $VRNA $LLY
1 · Reply
JarvisFlow
JarvisFlow Jul. 1 at 9:00 AM
Oppenheimer has updated their rating for Ascendis Pharma ( $ASND ) to Outperform with a price target of 215.
0 · Reply
CrispDry
CrispDry Jun. 25 at 2:49 PM
$ASND why is this so volatile?
1 · Reply
JarvisFlow
JarvisFlow Jun. 25 at 1:00 PM
Evercore ISI Group has adjusted their stance on Ascendis Pharma ( $ASND ), setting the rating to Outperform with a target price of 205 → 220.
0 · Reply
FannyPackin
FannyPackin Jun. 24 at 6:45 PM
$ASND easy $
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 18 at 4:11 PM
Attached are 11 recent larger comm'l-stage bio M&A transactions with the enterprise value paid as a multiple of cumulative 10-year revenue & gross margin projections (top) SWTX was acquired for 0.26X cumulative 10-year projected revenues (per SWTX mgmt/BOD), the lowest multiple in this peer group. IMGN was acquired @ 0.78X 10 year projected revenues (per IMGN mgmt/BOD) On the bottom see a pool of comm'l-stage peers some consider potential M&A candidates, and their current market cap as a multiple of 10-year projected revenues. $FOLD trades at the lowest multiple of 10-year analyst consensus revenue estimates (in this pool). $RARE may be technically lower but RARE's projections likely include contributions from unapproved products/pipeline. It appears $ASND trades at the highest multiple in this arbitrary peer group. This could be due to conviction in ASND's products & perceived lower risk. Yes there c/b astericks to each bio. This is not investment advice $TARS $BMRN
2 · Reply
RunnerSignals
RunnerSignals Jun. 17 at 4:12 PM
Analysts Playing Target Practice 🎯 $INTU $ZS $ASND catching price hikes while $ANF cools off. Is $FITB the sleeper pick? stocksrunner.com/news/2025-06-17-analysts-shake-up-targets-and-why-intu-zs-and-asnd-could-be-poised-for-a-breakout
0 · Reply
Estimize
Estimize Jun. 11 at 8:00 PM
Wall St is expecting -1.55 EPS for $ASND Q2 [Reporting 09/09 AMC] http://www.estimize.com/intro/asnd?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Jun. 10 at 3:27 PM
JP Morgan updates rating for Ascendis Pharma ( $ASND ) to Overweight, target set at 165 → 180.
0 · Reply